¼¼°èÀÇ ºÐÀÚÁø´Ü ½ÃÀå ±Ô¸ð´Â 2024³â¿¡ 270¾ï ´Þ·¯·Î Æò°¡µÇ¾ú°í, CAGR 4.2%¸¦ ³ªÅ¸³», 2034³â¿¡´Â 404¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.
ÀÌ·¯ÇÑ ²ÙÁØÇÑ ¼ºÀåÀÇ ¹è°æÀº Àü¿°º´ ȯÀÚ Áõ°¡, ºÐÀÚÁø´Ü ±â¼úÀÇ Áö¼ÓÀûÀÎ Çõ½Å, Áúº´ÀÇ Á¶±â ¹ß°ß¿¡ ´ëÇÑ ÀÇ½Ä Áõ°¡, Æ÷ÀÎÆ® ¿Àºê Äɾî(POC) Áø´Ü¿¡ ´ëÇÑ ¿ä±¸ ±ÞÁõ, ¼¼°è ³ëÀÎ Àα¸ÀÇ ±Þ¼ÓÇÑ È®´ë µî ¿©·¯ ¿äÀÎÀ» Áý¾àÇϰí ÀÖ½À´Ï´Ù.
ºÐÀÚÁø´ÜÀº DNA, RNA, ´Ü¹éÁúÀ» Æ÷ÇÔÇÑ À¯Àüü°ú ÇÁ·ÎÅ׿ȿ¡¼ »ý¹°ÇÐÀû ¸¶Ä¿¸¦ ºÐ¼®ÇÏ¿© Áúº´À» È®ÀÎÇÏ°í ¸ð´ÏÅ͸µÇÏ´Â µ¥ ÇʼöÀûÀÎ ±â¼úÀÔ´Ï´Ù. º¸´Ù ºü¸£°í Á¤È®ÇÑ Áø´Ü ¼Ö·ç¼ÇÀ» Á¦°øÇÒ ¼ö ÀÖ´Â °Ç° °ü¸® ½Ã½ºÅÛ¿¡¼ ÀÌ ±â¼úÀº Çö´ë ÀÓ»ó¿¡¼ Á¡Á¡ ´õ Áß½ÉÀûÀÎ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. Thermo Fisher Scientific, Hologic, Sysmex Corporation, Danaher Corporation ¹× Qiagen°ú °°Àº ÀÌ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº ÁøÈÇÏ´Â ¼¼°èÀÇ ÀÇ·á ¿ä±¸¸¦ ÃæÁ·½Ã۱â À§ÇØ Á¦Ç° ¶óÀξ÷À» Áö¼ÓÀûÀ¸·Î È®´ëÇϰí ÀÖ½À´Ï´Ù.
½ÃÀå ¹üÀ§ | |
---|---|
½ÃÀÛ ¿¬µµ | 2024³â |
¿¹Ãø ¿¬µµ | 2025-2034³â |
½ÃÀÛ ±Ý¾× | 270¾ï ´Þ·¯ |
¿¹Ãø ±Ý¾× | 404¾ï ´Þ·¯ |
CAGR | 4.2% |
ºÐÀÚÁø´ÜÀº À¯ÀüÀÚ Áúȯ, ¾Ï, °¨¿°Áõ µî Æø³ÐÀº ÁúȯÀÇ ½Äº°¿¡ ÇʼöÀûÀÎ °í°¨µµ·Î Á¤È®ÇÑ °Ë»ç¸¦ Æ÷ÇÔÇÕ´Ï´Ù. ÀÌ Á¤¹ÐµµÀÇ ³ôÀ̰¡ ¼±Áø±¹ ½ÃÀå°ú ½ÅÈï±¹ ½ÃÀåÀÇ ¾çÂÊ¿¡¼ ä¿ëÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. »ç¿ëµÈ ±â¼ú Áß¿¡¼ ÁßÇÕÈ¿¼Ò ¿¬¼â¹ÝÀÀ(PCR)Àº 2024³â Á¡À¯À² 70.4%·Î ½ÃÀåÀ» ¼±µµÇß½À´Ï´Ù. RNA¿Í DNA¸¦ Á¤È®ÇÏ°Ô ÁõÆøÇÏ°í ¹Ì·®ÀÇ À¯Àü ¹°Áúµµ °ËÃâÇÒ ¼ö ÀÖ´Â PCRÀº ƯÈ÷ °¨¿°Áõ ½ºÅ©¸®´×À̳ª À¯ÀüÀÚ °Ë»ç¿¡ ÀÖ¾î¼ Á¶±â ¹ß°ß¿¡ ÇʼöÀûÀÎ ÅøÀÌ µÇ°í ÀÖ½À´Ï´Ù.
Á¾¾ç °Ë»ç ºÐ¾ß´Â 2024³â¿¡ 21¾ï ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2034³â¿¡´Â 32¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î Àü¸ÁµË´Ï´Ù. ¼¼°è¿¡¼ ¾Ï ÀÌȯÀ²ÀÌ Áõ°¡Çϰí ÀÖ´Â °Í ¿Ü¿¡ Á¶±â Áø´Ü¿¡ ´ëÇÑ ¼ö¿ä°¡ ³ô¾ÆÁö°í ÀÖ´Â °ÍÀÌ Á¾¾çÇп¡ ÀÖ¾î¼ÀÇ °íµµÀÇ ºÐÀÚ °Ë»ç ÅøÀÇ µµÀÔÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÇコÄÉ¾î ½Ã½ºÅÛÀº ³ôÀº °¨µµ¿Í ƯÀ̼ºÀ» °¡´ÉÇÏ°Ô ÇÏ´Â ºÐÀÚ ±â¹Ý Àåºñ, ŰƮ, ½Ã¾à¿¡ ÅõÀÚÇϰí ȯÀÚÀÇ °á°ú¸¦ °³¼±ÇÏ°í ¾Ï °ü¸® ÇÁ·ÎÅäÄÝÀ» ÁøÇàÇϰí ÀÖ½À´Ï´Ù.
2024³â ¹Ì±¹ÀÇ ºÐÀÚÁø´Ü ½ÃÀå ±Ô¸ð´Â 104¾ï ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. ¹Ì±¹°ú ij³ª´Ù ½ÃÀåÀº Àü¿°º´ÀÇ Áö¼ÓÀûÀÎ Áõ°¡¿Í Â÷¼¼´ë Áø´Ü ±â¼úÀÇ °³¹ß°ú »ó¾÷È¿¡ ´ëÇÑ °·ÂÇÑ Áö¿øÀ¸·Î Å« ±â¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ¾ö°ÝÇÑ ±ÔÁ¦ ±âÁØÀÌ ¼ö¸³µÇ¾úÀ½¿¡µµ ºÒ±¸Çϰí Çõ½ÅÀûÀÎ Áø´Ü Àåºñ ¹× ŰƮ ¹èÆ÷°¡ ÇöÀúÇÏ°Ô Àå·ÁµÇ°í ÀÖ½À´Ï´Ù. ±â¼úÀÇ Áøº¸¿Í Á¤±³ÇÑ ºÐÀÚ °Ë»ç Ç÷§ÆûÀÇ ±¤¹üÀ§ÇÑ Ã¤¿ëÀÌ ºÏ¹Ì ½ÃÀåÀÇ Ãß°¡ °ßÀÎ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.
¼¼°èÀÇ ºÐÀÚÁø´Ü ½ÃÀå¿¡¼ »ç¾÷À» Àü°³ÇÏ´Â ÁÖ¿ä ±â¾÷À¸·Î´Â F. Hoffmann-La Roche, Qiagen, Agilent Technologies, Biocartis, Thermo Fisher Scientific, Siemens Healthineers, Abbott Laboratories, Quidel Ortho Corporation, Bio-Rad Laboratories, Illumina, Becton, Dickinson Lifesciences, Biomerieux, Danaher Corporation, Hologic µîÀÌ ÀÖ½À´Ï´Ù. °æÀïÀÌ ½ÉÇÑ ºÐÀÚÁø´Ü ¿µ¿ª¿¡¼ÀÇ ÁöÀ§¸¦ ±»È÷±â À§ÇØ °¢»ç´Â Àü·«Àû Á¦ÈÞ, ÇÕº´, Àμö¸¦ Àû±ØÀûÀ¸·Î ÁøÇàÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ³ôÀº 󸮷®, ÀÚµ¿È, ¸ÖƼÇ÷º½º °Ë»ç Ç÷§ÆûÀ» Çõ½ÅÇϱâ À§ÇÑ R&D ÅõÀÚ¿¡µµ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. Á¦Ç° Æ÷Æ®Æú¸®¿À È®´ë, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ Ãëµæ, »õ·Î¿î Áö¿ª ½ÃÀå ÁøÀÔÀº ±â¾÷ÀÌ ¼¼°è ¹ßÀÚ±¹À» È®´ëÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¶ÇÇÑ AI¿Í µðÁöÅÐ Ç÷§ÆûÀÇ ÅëÇÕÀº Áø´Ü Á¤È®µµ¿Í ¼Óµµ¸¦ Çâ»ó½ÃŰ°í ±â¼úÀû ÀÌÁ¡À» Á¦°øÇÕ´Ï´Ù.
The Global Molecular Diagnostics Market was valued at USD 27 billion in 2024 and is estimated to grow at a CAGR of 4.2% to reach USD 40.4 billion by 2034. This steady growth is being fueled by multiple converging factors such as rising cases of infectious diseases, continuous innovation in molecular diagnostic technologies, growing awareness of early disease detection, the surging need for point-of-care (POC) diagnostics, and the rapid expansion of the global elderly population.
Molecular diagnostics serves as a vital technique in identifying and monitoring diseases by analyzing biological markers in the genome and proteome, including DNA, RNA, and proteins. With healthcare systems under pressure to deliver faster and more accurate diagnostic solutions, this technique is playing an increasingly central role in modern clinical practice. Major players in the market-such as Thermo Fisher Scientific, Hologic, Sysmex Corporation, Danaher Corporation, and Qiagen-continue to expand their offerings to meet evolving global health needs.
Market Scope | |
---|---|
Start Year | 2024 |
Forecast Year | 2025-2034 |
Start Value | $27 Billion |
Forecast Value | $40.4 Billion |
CAGR | 4.2% |
Molecular diagnostics involves highly sensitive and accurate tests that are critical for identifying a wide array of conditions, including genetic disorders, cancers, and infectious diseases. This accuracy is driving its adoption across both developed and emerging markets. Among the technologies used, polymerase chain reaction (PCR) led the market in 2024 with a 70.4% share. Its precise amplification of RNA and DNA and ability to detect even the smallest quantities of genetic material make PCR an essential tool for early detection, especially for infectious disease screening and genetic testing.
The oncology testing segment was valued at USD 2.1 billion in 2024 and is projected to reach USD 3.2 billion by 2034. Increasing cancer incidence across the globe, along with a rising demand for early diagnosis, is driving the uptake of advanced molecular testing tools in oncology. Healthcare systems are investing in molecular-based instruments, kits, and reagents that enable high sensitivity and specificity, improving patient outcomes and advancing cancer management protocols.
United States Molecular Diagnostics Market generated 10.4 billion in 2024. The U.S. and Canadian markets are witnessing significant momentum due to the continued rise of infectious diseases and strong support for the development and commercialization of next-generation diagnostic technologies. Even with strict regulatory standards in place, there is notable encouragement for the rollout of innovative diagnostic instruments and kits. Technological advancement and widespread adoption of sophisticated molecular testing platforms are helping to drive the market further in North America.
Leading companies operating in the Global Molecular Diagnostics Market include F. Hoffmann-La Roche, Qiagen, Agilent Technologies, Biocartis, Thermo Fisher Scientific, Siemens Healthineers, Abbott Laboratories, QuidelOrtho Corporation, Bio-Rad Laboratories, Illumina, Becton, Dickinson and Company, Sysmex Corporation, Huwel Lifesciences, Biomerieux, Danaher Corporation, and Hologic. To solidify their positions in the competitive molecular diagnostics space, companies are actively pursuing strategic alliances, mergers, and acquisitions. They are also focused on investing in R&D to innovate high-throughput, automated, and multiplex testing platforms. Expanding product portfolios, obtaining regulatory approvals, and entering new regional markets are helping players scale their global footprint. Additionally, integration of AI and digital platforms is enhancing diagnostic accuracy and speed, providing a technological edge.